​

Funding Round

Series B - Fusion Pharmaceuticals

Series B - Fusion Pharmaceuticals

Investment Firm

Overview

Fusion Pharmaceuticals is a clinical-stage oncology company focused on developing radiopharmaceuticals.

Announced Date

Apr 01, 2019

Funding Type

Series B

Highlights

Location

North America

Social

Investor Lead

OrbiMed

OrbiMed

OrbiMed is a debt and early_stage_venture and late_stage_venture and post_ipo and private_equity and seed and venture firm.

Varian

Varian

No designation

Participant Investors

11

Investor Name
Participant InvestorOrbiMed
Participant InvestorGenesys Capital
Participant InvestorPivotal bioVenture Partners
Participant InvestorSeroba Life Sciences
Participant InvestorAdams Street Partners

Round Details and Background

Fusion Pharmaceuticals raised $105000000 on 2019-04-01 in Series B

Fusion Pharmaceuticals is a clinical-stage oncology company focused on developing radiopharmaceuticals.

Company Funding History

5

Announcment DateTransaction NameNumber Of InvestorsLead InvestorMoney Raised
Jan 13, 2020
Venture Round - Fusion Pharmaceuticals
1-19.9M
Feb 13, 2023
Post-IPO Equity - Fusion Pharmaceuticals
5-60.0M
Sep 25, 2017
Series A - Fusion Pharmaceuticals
8-21.0M
Feb 23, 2017
Series A - Fusion Pharmaceuticals
5-25.0M

Recent Activity

There is no recent news or activity for this profile.